Nothing Special   »   [go: up one dir, main page]

EA201790563A1 - Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой - Google Patents

Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой

Info

Publication number
EA201790563A1
EA201790563A1 EA201790563A EA201790563A EA201790563A1 EA 201790563 A1 EA201790563 A1 EA 201790563A1 EA 201790563 A EA201790563 A EA 201790563A EA 201790563 A EA201790563 A EA 201790563A EA 201790563 A1 EA201790563 A1 EA 201790563A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
woodlizumab
heavy
degree
treatment
Prior art date
Application number
EA201790563A
Other languages
English (en)
Other versions
EA034864B1 (ru
EA201790563A8 (ru
Inventor
Ги Брюссель
Кристофер О'Брайен
Джеймс Зангрилли
Тушар Шах
Original Assignee
Сефалон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сефалон, Инк. filed Critical Сефалон, Инк.
Publication of EA201790563A1 publication Critical patent/EA201790563A1/ru
Publication of EA201790563A8 publication Critical patent/EA201790563A8/ru
Publication of EA034864B1 publication Critical patent/EA034864B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

В настоящем документе раскрыты способы лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой у пациента, включающие: 1) идентификацию пациента, имеющего эозинофильную астму со степенью тяжести от умеренной до тяжелой, при этом симптомы пациента недостаточно контролируются текущим лекарственным средством против астмы и уровень эозинофилов в крови у пациента составляет 400/мкл или более; и 2) введение указанному пациенту терапевтически эффективной дозы реслизумаба.
EA201790563A 2014-09-08 2015-08-28 Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой EA034864B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462047248P 2014-09-08 2014-09-08
US201462091150P 2014-12-12 2014-12-12
US201562168007P 2015-05-29 2015-05-29
US201562191690P 2015-07-13 2015-07-13
PCT/US2015/047357 WO2016040007A1 (en) 2014-09-08 2015-08-28 Use of reslizumab to treat moderate to severe eosinophilic asthma

Publications (3)

Publication Number Publication Date
EA201790563A1 true EA201790563A1 (ru) 2017-08-31
EA201790563A8 EA201790563A8 (ru) 2017-11-30
EA034864B1 EA034864B1 (ru) 2020-03-31

Family

ID=54066234

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790563A EA034864B1 (ru) 2014-09-08 2015-08-28 Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой

Country Status (19)

Country Link
US (2) US9815894B2 (ru)
EP (1) EP3191513B1 (ru)
KR (1) KR102495432B1 (ru)
CN (1) CN107073114B (ru)
AU (1) AU2015315628A1 (ru)
CA (1) CA2962944A1 (ru)
CY (1) CY1123501T1 (ru)
DK (1) DK3191513T3 (ru)
EA (1) EA034864B1 (ru)
ES (1) ES2811124T3 (ru)
HR (1) HRP20201307T1 (ru)
HU (1) HUE050202T2 (ru)
PL (1) PL3191513T3 (ru)
PT (1) PT3191513T (ru)
RS (1) RS60701B1 (ru)
SI (1) SI3191513T1 (ru)
UA (1) UA122670C2 (ru)
WO (1) WO2016040007A1 (ru)
ZA (1) ZA201702247B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
EP3634434A4 (en) * 2017-05-12 2021-06-09 The Regents of The University of California TREATMENT AND DETECTION OF DYSBIOSIS
TWI801425B (zh) 2017-09-29 2023-05-11 大陸商江蘇恆瑞醫藥股份有限公司 Il-5 抗體、其抗原結合片段及醫藥用途
JP2022528230A (ja) 2019-03-29 2022-06-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
WO2020231843A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT67943A (en) 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
EP2274009B1 (en) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
TWI708944B (zh) * 2010-12-16 2020-11-01 美商建南德克公司 關於th2抑制作用之診斷及治療

Also Published As

Publication number Publication date
US9815894B2 (en) 2017-11-14
EP3191513B1 (en) 2020-06-24
RS60701B1 (sr) 2020-09-30
HRP20201307T1 (hr) 2020-11-27
KR20170072197A (ko) 2017-06-26
WO2016040007A1 (en) 2016-03-17
ZA201702247B (en) 2018-08-29
DK3191513T3 (da) 2020-08-24
KR102495432B1 (ko) 2023-02-03
NZ730541A (en) 2023-10-27
CN107073114B (zh) 2022-01-14
UA122670C2 (uk) 2020-12-28
EA034864B1 (ru) 2020-03-31
SI3191513T1 (sl) 2020-12-31
EP3191513A1 (en) 2017-07-19
HUE050202T2 (hu) 2020-11-30
ES2811124T3 (es) 2021-03-10
EA201790563A8 (ru) 2017-11-30
CN107073114A (zh) 2017-08-18
PL3191513T3 (pl) 2021-02-08
CA2962944A1 (en) 2016-03-17
US20160102144A1 (en) 2016-04-14
US10577414B2 (en) 2020-03-03
US20180030131A1 (en) 2018-02-01
PT3191513T (pt) 2020-07-31
AU2015315628A1 (en) 2017-04-20
CY1123501T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
EP4272757A3 (en) Modified nk-92 cells for treating cancer
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
PH12018502593A1 (en) Combinations of linagliptin and metformin
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
AR101740A1 (es) Terapia de combinación y composiciones
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016090024A3 (en) Combination therapy for treatment of cancer
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
EA201691525A1 (ru) Применение кладрибина для лечения оптиконевромиелита

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM